calithera
biosciences
awarded
cystic
fibrosis
foundation
support
clinical
development
arginase
inhibitor
south
san
francisco
globe
newswire
calithera
biosciences
nasdaq
cala
biotechnology
company
focused
discovering
developing
novel
drugs
treatment
cancer
diseases
awarded
cystic
fibrosis
foundation
award
support
clinical
development
calithera
investigational
arginase
inhibitor
promotes
higher
tissue
levels
nitric
oxide
reduce
risk
infections
people
cystic
fibrosis
cf
grateful
cystic
fibrosis
foundation
support
accelerate
clinical
development
potentially
new
treatment
often
devastating
disease
said
susan
molineaux
president
chief
executive
officer
calithera
based
preclinical
data
unique
pathology
cystic
fibrosis
believe
arginase
inhibition
represents
novel
promising
opportunity
improve
cf
cystic
fibrosis
progressive
genetic
disease
causes
persistent
lung
infections
limits
ability
breathe
time
research
cf
patients
demonstrated
increased
arginase
activity
correlates
directly
worsened
lung
function
decreased
airway
nitric
oxide
promoting
pathogen
colonization
preclinical
studies
conducted
calithera
collaborators
validated
arginase
inhibition
therapeutic
approach
cf
demonstrated
inhibiting
arginase
may
reduce
infection
improve
lung
function
people
cf
calithera
ongoing
randomized
multiple
ascending
study
exploring
versus
placebo
adults
cystic
fibrosis
chronic
infection
pseudomonas
aeruginosa
stable
cystic
fibrosis
medications
including
cystic
fibrosis
transmembrane
conductance
regulator
cftr
modulators
study
evaluating
safety
pharmacokinetics
pharmacodynamics
biological
activity
four
dose
cohorts
versus
placebo
calithera
expects
share
interim
data
investigational
selective
oral
inhibitor
human
arginase
calithera
developing
treatment
cystic
fibrosis
arginine
required
nitric
oxide
production
critical
body
ability
fight
infections
maintain
pulmonary
airway
function
inhibiting
arginase
may
allow
body
improve
production
subsequently
better
combat
cf
wholly
owned
calithera
calithera
calithera
biosciences
biopharmaceutical
company
pioneering
discovery
development
targeted
therapies
disrupt
cellular
metabolic
pathways
preferentially
block
tumor
cells
enhance
activity
driven
commitment
rigorous
science
passion
improving
lives
people
impacted
cancer
diseases
calithera
advancing
pipeline
oral
therapeutics
meaningfully
expand
treatment
options
available
patients
calithera
headquartered
south
san
francisco
california
information
calithera
please
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
anticipate
estimate
intend
poised
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
include
related
calithera
clinical
trials
clinical
commercial
potential
product
candidates
presentation
interim
data
randomized
trial
cystic
fibrosis
patients
impact
patients
cystic
fibrosis
amount
award
cystic
fibrosis
foundation
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
potential
product
candidates
calithera
develops
may
progress
clinical
development
receive
required
regulatory
approvals
within
expected
timelines
calithera
clinical
trials
may
confirm
safety
potency
product
characteristics
described
assumed
press
release
product
candidates
may
beneficial
patients
successfully
commercialized
addition
pandemic
may
result
delays
calithera
studies
trials
failure
meet
expectations
respect
foregoing
matters
may
negative
effect
calithera
stock
price
additional
information
concerning
risk
factors
affecting
calithera
business
found
calithera
periodic
filings
securities
exchange
commission
statements
guarantees
future
performance
speak
date
hereof
except
required
law
calithera
disclaims
obligation
update
statements
reflect
future
events
circumstances
source
calithera
biosciences
inc
contacts
investor
relations
jennifer
mcnealey
calithera
ir
media
michele
parisi
sam
brown
micheleparisi
